Drugs / nanosilver
nanosilver
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04213716 | Jun 2015 → Jun 2016 | — | Cairo University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | nanosilver | “1ml of nanosilver solution 30ppm concentration mixed with 100 mg of calcium hydroxide powder used as intracanal medication” NCT04213716 ↗ |
| Known as | nanosilver solution | “1ml of nanosilver solution 30ppm concentration mixed with 100 mg of calcium hydroxide powder used as intracanal medication” NCT04213716 ↗ |
| Known as | silver nano particulate solution | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04213716 ↗ |
| Route | Other | “used as intracanal medication” NCT04213716 ↗ |